Premium
Glutamate Cysteine Ligase Modifier (GCLM) Subunit Gene Is Not Associated with Methamphetamine‐Use Disorder or Schizophrenia in the Japanese Population
Author(s) -
Kishi Taro,
Ikeda Masashi,
Kitajima Tsuyoshi,
Yamanouchi Yoshio,
Kinoshita Yoko,
Kawashima Kunihiro,
Inada Toshiya,
Harano Mutsuo,
Komiyama Tokutaro,
Hori Toru,
Yamada Mitsuhiko,
Iyo Masaomi,
Sora Ichiro,
Sekine Yoshimoto,
Ozaki Norio,
Ujike Hiroshi,
Iwata Nakao
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1432.022
Subject(s) - gclm , meth , schizophrenia (object oriented programming) , single nucleotide polymorphism , genetic association , medicine , genetics , psychiatry , biology , gene , genotype , chemistry , dna ligase , polymer , monomer , organic chemistry , acrylate , gclc
A recent study showed a significant association between schizophrenia in European samples and the glutamate cysteine ligase modifier (GCLM) subunit gene, which is the key glutathione (GSH)‐synthesizing enzyme. Since the symptoms of methamphetamine (METH)‐induced psychosis are similar to those of schizophrenia, the GCLM gene is thought to be a good candidate gene for METH‐use disorder or related disorders. To evaluate the association between the GCLM gene and METH‐use disorder and schizophrenia, we conducted a case‐control study of Japanese subjects (METH‐use disorder, 185 cases; schizophrenia, 742 cases; and controls, 819). Four SNPs (2 SNPs from an original report and JSNP database, and 2 “tagging SNPs” from HapMap database) in the GCLM gene were examined in this association analysis; one SNP showed an association with both METH‐use disorder and METH‐induced psychosis. After Bonferroni's correction for multiple testing, however, this significance disappeared. No significant association was found with schizophrenia. Our findings suggest that a common genetic variation in the GCLM gene might not contribute to the risk of METH‐use disorder and schizophrenia in the Japanese population.